![\"\"](\"https:\/\/dexpatent.com\/insights\/wp-content\/uploads\/2021\/12\/economic-1.png\")
<\/p>\n<\/p>\n
GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels, has announced the upcoming release of its sensitive PCR tests to monitor the coronavirus Omicron variant, B.1.1.529. (Source- prnewswire)<\/p>\n
Biocartis Group NV announced that the company performed an in-silico analysis which concluded that the Idylla\u2122 SARS-CoV-2 Test (CE-IVD) and the Idylla\u2122 SARS-CoV-2\/Flu\/RSV1 Panel (CE-IVD) detect the currently available B.1.1.529\/Omicron sequences, the new variant of concern causing COVID-19 disease. (Source- globenewswire)<\/p>\n
Tevogen Bio announced the issuance of a patent which significantly reinforces Tevogen\u2019s intellectual property<\/strong><\/a> position in use of SARS-CoV-2 specific Cytotoxic CD8+ T Lymphocytes (CTL) immunotherapy for treatment of COVID-19. Dr. Neal Flomenberg, MD, said, our\u00a0 therapeutic targets are not affected in the Delta variant and appear preserved in the Omicron variant as well. (Source- businesswire)<\/p>\n A research team at Pohang University of Science and Technology (POSTECH) has developed a diagnostic technology to detect the Covid-19 variant Omicron in just 20 minutes. The researchers are preparing to apply for a patent <\/a><\/strong>for commercialization. (Source- koreabiomed)<\/p>\n Gb Sciences has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With the arrival of Omicron variant, Gb Sciences plans to move quickly through the development stages for this novel CRS therapy. (Source- globenewswire)<\/p>\n The Copper fresh mask\u2019s introduction, comes at an apt time, considering the detection of the Omicron variant just over two weeks ago. The masks offer dual-side protection<\/strong><\/a> with 99.9% bacterial filtration. The mask kills the virus just a few minutes after it touches the mask. (Source – iol.co)<\/p>\n GreenLight Biosciences (ENVI) and IAVI, a nonprofit scientific research organization announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant. GreenLight’s Covid-19 vaccine candidate will begin clinical trials in South Africa next year. (Source-\u00a0 prnewswire)<\/p>\n Seegene Inc. unveiled series of diagnostic test that detects the ever-changing COVID-19 variant landscape<\/a>.<\/strong> The Novaplex\u2122 SARS-CoV-2 variants VII assay addresses Omicron and its stealth version, as well as other variants. (Source-\u00a0 prnewswire)<\/p>\n","protected":false},"excerpt":{"rendered":"POSTECH team develops testing method to detect Omicron variant<\/strong><\/h3>\n
Gb Sciences targets COVID-19 treatment as Omicron variant arrives<\/strong><\/h3>\n
Copper fresh masks to restrict the spread of Covid-19<\/strong><\/h3>\n
GreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate<\/strong><\/h3>\n
Seegene\u2019s new PCR test identifies the Omicron variant, its stealth version and all VOCs in a single tube<\/strong><\/h3>\n